Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FS120

Bispecific antibody · Immune activation, directed at OX40 (TNFRSF4) and CD137 (4-1BB) (TNFRSF9)

Phase 1 Most advanced trial (none active)

What is FS120?

FS120 is a tetravalent IgG1 bispecific antibody that simultaneously binds and activates the co-stimulatory receptors OX40 and CD137 on T-lymphocytes and natural killer cells. It is being studied in advanced and metastatic cancer, including in combination with pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pembrolizumab (KEYTRUDA)
Drug type
Bispecific antibody
Targets
OX40 (TNFRSF4), CD137 (4-1BB) (TNFRSF9)
Mechanism
Immune activation, directed at OX40 (TNFRSF4) and CD137 (4-1BB) (TNFRSF9)
Pathways
T-cell co-stimulation, T-cell proliferation and survival, NK cell activation
Therapy area
Oncology
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
CAN96F6UCF

Conditions studied

Advanced CancerMetastatic Cancer

Other drugs acting on TNFRSF4 / TNFRSF9

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.